Fidelity Advisor Biotechnology C: (MF: FBTIX)
NAV
$15.87
NAV Day Change
-0.09 (-0.56%)
May 22 06:05 PM ET
General Information As Of 04/30/13
| %Yield | 0.00 |
| %SEC Yield | NA |
| %YTD Return (as of 04/30/13) | 26.87 |
| Objective* | Equity - Sector Health |
| Peer* | HL MG |
Portfolio Statistics
| %Unrealized Gain YTD | 21.11 |
| Net Assets (Mil $) 04/30/2013 | 105.17 |
| %Turnover 04/30/2013 | 20.00 |
Fees
| %Max Sales Load | NA |
| %Min Sales Load | NA |
| %Max Deferred Load | NA |
Expenses
| %Max 12b-1 Fee | 0.00 |
| %Max Management Fee | 0.56 |
| Redemption Fee | 0.75 |
| Expense Ratio | 0.92 |
Allocation
| Large Growth | 50.48 |
| Large Value | 0.00 |
| Small Growth | 0.00 |
| Small Value | 0.00 |
| Foreign Stock | 0.00 |
| Emerging Market | 0.00 |
| Precious Metal | 0.00 |
| Intermediate Bond | 0.00 |
| Foreign Bond | 0.00 |
| High Yield Bond | 0.00 |
Portfolio Information
Composition
| As of 01/31/2013 | %of Net Assets |
| Stock | 96.49 |
| Cash | 9.98 |
| Bonds | 0.00 |
| Preferred | 0.26 |
| Convertibles | 0.04 |
| Foreign Stock | 1.54 |
| Foreign Bonds | 0.00 |
| Hedge | 0.00 |
| Other | -6.76 |
Sector / Country Weightings
| As of 04/30/2013 | % of Portfolio |
|---|---|
| Health | 61.72 |
| Services | 20.18 |
| Other | 10.43 |
| Industrial Cyclical | 6.77 |
| Technology | 0.62 |
| Retail Trade | 0.26 |
| Energy | 0.01 |
| Non-Durable | 0.01 |
Portfolio Holdings
| Top Equity Holdings (As of 10/31/2012) | % of Portfolio | Value (Mil$) |
|---|---|---|
| AMGEN INC | 13.10 | 24.60 |
| GILEAD SCIENCES INC | 13.06 | 24.52 |
| BIOGEN IDEC INC | 7.01 | 13.17 |
| REGENERON PHARMACEUTICALS | 4.74 | 8.91 |
| CELGENE CORP | 4.48 | 8.42 |
| ONYX PHARMACEUTICALS INC | 4.10 | 7.69 |
| MEDIVATION INC | 3.70 | 6.95 |
| VERTEX PHARMACEUTICALS IN | 3.64 | 6.83 |
| ALEXION PHARMACEUTICALS I | 2.24 | 4.21 |
Contact Information
| Family | Fidelity |
| Addrerss | 82 Devonshire St Boston, MA 02109 |
| Phone | 800 544-6666 |
Zacks Premium Research
Zacks Mutual Fund Rank: 1 - Strong Buy 
| #1 |
Fund Description
Fidelity Advisor Biotechnology Fund, Class I was incepted in December 2000 and is managed by the Fidelity Group. The objective of the fund is to seek capital appreciation. The fund normally invests primarily in common stocks. The fund normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund offers dividends and capital gains twice a year in September and December.
Stock Holding % of Net Assets
| As Of | 01/31/2013 |
| Total Issues | 129 |
| Avg. P/E | 40.20 |
| Avg. P/Book | 5.74 |
| Avg. EPS Growth | 15.34 |
| Avg. Market Value (Mil $) | 22,404 |
Risk
| 3 Year | 5 Year | 10 Year | |
|---|---|---|---|
| Beta | 1.03 | 0.74 | 0.78 |
| Alpha | 13.22 | 15.25 | 7.05 |
| R Squared | 0.65 | 0.45 | 0.39 |
| Std. Dev. | 19.06 | 20.92 | 18.68 |
| Sharpe | 1.53 | 1.00 | 3.00 |
Shareholder Information
| Manager | Rajiv Kaul |
| Since | 10/05 |
| Manager Rating | 6.30 |
| Inception Date | 12/27/2000 |
| Shareholders | NA |
| Dividends Paid | S |
| Minimum Initial Investment | $2,500 |
| Minimum Subsequent Investment | $0 |
| IRA Minimum | $500 |
| IRA Available | Y | Check Writing | N | Phone Invest | Y |
| Phone Exchange | Y | Phone Redeem | Y | Auto Invest | Y |
| Wire Redeem | Y | Wire Fee | Y | Wire Transfer | Y |
